Alnylam Pharmaceuticals (ALNY) shares rallied 8.5% in the last trading session to close at $243.27. This move can be attributable to notable volume with a higher number of shares being traded than ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Explore Alnylam Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALNY. Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like ...

Alnylam already markets the medicine for people with a form of the condition that affects the nerves, but has long looked to an approval in cardiomyopathy as the kind of revenue driver that can ...

Shares in Alnylam were up almost 56% at one point yesterday, while rival Ionis saw its shares slump 9%. Shares in The Medicines Company were also up 5.7% thanks to an RNAi licensing deal with Alnylam.

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

The Food and Drug Administration cleared Alnylam Pharmaceuticals’ treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.